



Zasocitinib Shows Consistent Skin Clearance in Difficult-to-Treat Psoriasis

Zasocitinib demonstrated high rates of skin clearance across the scalp, palms and soles, and nails in Phase 3 studies of adults with moderate-to-severe plaque psoriasis. Responses were sustained through week 24, supporting continued development of the once-daily oral TYK2 inhibitor.

[Learn More](#)

Fadeucravacitinib Meets Phase 3 Endpoint in Plaque Psoriasis

Fadeucravacitinib (ICP-488) met the primary endpoint in a Phase 3 study of moderate-to-severe plaque psoriasis, with multiple secondary endpoints also showing significant improvements. The oral TYK2 inhibitor had a favorable safety profile with no new safety signals.

[Read More](#)



Rezpegaldesleukin Advances to Phase 3 in Atopic Dermatitis

Nektar Therapeutics initiated two global Phase 3 trials evaluating rezpegaldesleukin in patients ages 12 and older with moderate-to-severe atopic dermatitis. The three-study ZENITH AD program will include both treatment-naïve and treatment-experienced patients.

[Learn More](#)

VTAMA Shows Early, Consistent Improvement in Atopic Dermatitis

Pooled Phase 3 data showed VTAMA cream improved skin clearance and disease severity in pediatric patients and adults with moderate-to-severe atopic dermatitis, with improvements seen as early as week 2 and continuing through week 8.

[More Details](#)

ADBRY (tralokinumab) Shows Long-Term Safety in Children With Atopic Dermatitis

Phase 2 TRAPEDS-1 data showed tralokinumab had an expected pharmacokinetic profile and was generally well tolerated in children ages 6 to 11 with moderate-to-severe atopic dermatitis, with no new safety signals through 172 weeks.

[Read More](#)

Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis

Sanofi will discontinue clinical development of amlitelimab in moderate-to-severe atopic dermatitis and will not pursue global regulatory submissions. The company determined that the overall efficacy and safety evidence did not support further development in AD.

[More Details](#)

Across the pipeline, dermatology continues to advance new and differentiated treatment options, with positive data in psoriasis and atopic dermatitis, expanded pediatric development, and ongoing evaluation of novel therapies.

CPE Spotlight

Two New CPE Offerings!

At the Table™ Program

What if your next educational program felt more like a conversation than a presentation?

At the Table brings:

- A curated, KOL-led experience
- Deeper, more meaningful clinical dialogue than traditional educational settings allow
- End-to-end CPE management, from recruitment and logistics through post-program follow-up



Dedicated KOL Brand Ambassador Program

Looking to get more strategic value from your KOL relationships beyond individual engagements?

The Dedicated KOL Brand Ambassador Program provides:

- Transformation of one-time KOL engagements into an ongoing, coordinated presence across key HCP touchpoints
- A consistent, credible presence that extends across multiple HCP engagement opportunities
- CPE support throughout the KOL engagement process, from identification and vetting through contracting and logistics



Explore Our New Website

Our new website offers a closer look at how CPE connects science, strategy, and education to support meaningful healthcare engagement.

[Visit us at cpeducate.com](#)

Below is a list of CPE's core service offerings for clients across marketing and medical affairs. While these reflect our core capabilities, our team regularly customizes solutions to meet evolving client needs.

Medical Affairs

Asynchronous Engagements
KOL Identification & Contracting
MOA Visualization
MSL Training
Patient Education
Poster Presentations
Scientific Platform Development

Medical Affairs Marketing

Advisory Boards
(Virtual or In-Person)
Conference Planning
Content Development
Core Slide Decks
KOL Engagements
Publications

Marketing

Branding & Visual Aids
Healthcare Event Production Management
Launch Preparation
Product Theater Planning & Logistics
Speaker Bureau Services
Speaker Training
Technical Productions

Our two new offerings – the **At the Table Program** and **Dedicated KOL Brand Ambassador Program** – are designed to help brands create deeper HCP conversations and strategic, ongoing KOL engagements.

Want to see how they could work for your brand? Reply to this email and let's explore the possibilities.

With appreciation,

Allison Goldberg, MPA
Associate Vice President
CPE Communications
Cell: 917-509-9583
agoldberg@cpeducate.com

When you're ready to explore how the CPE Communications Team can support your company, contact Allison at agoldberg@cpeducate.com